Oncternal Therapeutics Inc (ONCT)

[stocking4ms]

Just a brief summary:

June 2, 2015. Compliance regained for delisting by 9/28/15.
December 23, 2015. Letter for new delisting date: 6/20/16.

May 4, 2016. Annual Meeting of Stockholders.
- To approve the election of the two nominees for director named in the accompanying proxy statement.
- To ratify the appointment of Ernst & Young LLP as GTx's independent registered public accounting firm for 2016.
- To approve a series of alternate amendments to GTx's charter to effect a reverse stock split.
- To approve a series of alternate amendments to GTx's charter to effect a corresponding reduction in the number of authorized shares of GTx's common stock if the reverse stock split proposal is approved and implemented.

From March 15, 2016 10-K form:
"We currently estimate we have sufficient funding through the end of 2016 to allow us to obtain the results from the patients enrolled in the first stage of each clinical trial, but our ability to enroll patients to the second stage and complete both of these clinical trials will require us to seek sufficient additional funding."
We anticipate top-line data from this Phase 2 clinical trial of enobosarm in SUI by the end of 2016.

Stocks tend to rise leading to a forward reverse split.
R/S next month and offering before EOY. Not a great scenario.